While the clinical benefits of Drisapersen and Eteplirsen are not proven at all, dying boys deserve a choice. Even if 1 child could be saved by approving Drisapersen and Eteplirsen, don't we owe it to that child to give them a chance at life?
we already had the shares in $25 so longs are so far clearly a winner and company issued the shares and have enough money to finish the trials. Lets see how it rolls out.
we have 30 minutes left. so many shorts trapped in this. and they have margins call coming soon. and no share available for them to cover as institutions own 90%. Average will be 300K after this day. We will go $45 in 1 week. Mark my words.
Lets see what price they will take it to in 3 months.. Long term IQNT is a strong buy.